Comprehensive upfront biomarker testing, including RAS, BRAF, HER2, and MSI status, now anchors first-line treatment selection in metastatic colorectal cancer, though reflexive testing adoption still varies across practice settings nationwide.
Choosing between FOLFOX and FOLFIRI, and deciding when to shift to maintenance therapy, requires balancing prior treatment exposure, patient lifestyle, and the limited pool of active agents in colorectal cancer.
